Hunan Jingfeng Pharmaceutical Co., Ltd. (000908.SZ) announced Thursday that it had received approval from the U.S. Food and Drug Administration (FDA) for its prednisone tablet ANDA application.
The approval qualifies the company to sell prednisone tablets in the U.S. market which could help it expand overseas market and positively affect its performance, according to a filing with the Shenzhen Stock Exchange.
It is noted that the application was filed by GeneYork Pharmaceuticals Group LLC, a joint venture between its subsidiary Sungen Pharma, LLC and Tianjin Kingyork Group Co., Ltd.
Prednisone tablet sales totaled approximately 139 million U.S. dollars, 134 million U.S. dollars, and 139 million U.S. dollars in the U.S. market in 2015-2017, respectively, according to data service provider IMS.
The approval qualifies the company to sell prednisone tablets in the U.S. market which could help it expand overseas market and positively affect its performance, according to a filing with the Shenzhen Stock Exchange.
It is noted that the application was filed by GeneYork Pharmaceuticals Group LLC, a joint venture between its subsidiary Sungen Pharma, LLC and Tianjin Kingyork Group Co., Ltd.
Prednisone tablet sales totaled approximately 139 million U.S. dollars, 134 million U.S. dollars, and 139 million U.S. dollars in the U.S. market in 2015-2017, respectively, according to data service provider IMS.
Latest comments